期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

不同剂量阿托伐他汀对无症状颈动脉斑块消退作用比较 被引量：15

下载PDF
导出
摘要 目的采用颈动脉超声观察不同剂量阿托伐他汀治疗无症状颈动脉斑块的疗效和安全性。方法对参加健康体检时经彩超检查发现有颈动脉斑块的观察病例64例,分为低剂量组(阿托伐他汀10mg/d),高剂量组(阿托伐他汀40mg/d),共服药6个月,观察用药前、3个月和6个月时血脂变化情况、内-中膜厚度(IMT)及药物的副作用。结果与治疗前比较,10mg阿托伐他汀治疗3个月后,LDL-C呈显著性下降(P<0·05),而TC,IMT无明显变化;6个月后TC,LDL-C下降呈显著性差异(P<0·05),且LDL-C水平比3个月时也呈显著性下降,而IMT下降没有显著性差异;服用40mg阿托伐他汀3个月,TC,LDL-C即呈显著性下降(P<0·05),IMT下降虽然没有显著性差异,但呈下降趋势;6个月后,TC,LDL-C及IMT下降均呈显著性差异(P<0·05)。两组之间比较,3个月时高剂量治疗组LDL-C,IMT下降有显著性差异(P<0·05),6个月时TC,LDL-C,IMT下降均有显著性差异(P<0·05)。高剂量治疗组中有1例观察者于6个月后出现肝脏转氨酶轻度增高,但未达两倍。结论低剂量阿托伐他汀的治疗强度是不够的,坚持服用高剂量阿托伐他汀,可以在降脂的同时,达到稳定与消退斑块的作用,同时也是安全的。
作者 杨玲 薛世荣
机构地区 南方医科大学附属南海医院
出处 《广东医学》 CAS CSCD 北大核心 2008年第6期1041-1043,共3页 Guangdong Medical Journal
关键词 阿托伐他汀 超声 颈动脉斑块 低密度脂蛋白胆固醇
分类号 R589.2 [医药卫生—内分泌] R743.33 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献11

  • 1O'LEARY D H, POLAK J F, KRONMAL R A, et al. Carotid -artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group[J]. N Engl J Med, 1999, 340:14 -22.
  • 2GRUNDY S M, CLEEMAN J I, MERZ C N, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines[J]. Circulation, 2004, 110 : 227 - 239.
  • 3SEVER P S, DAHLOF B, POULTER N R, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo - Scandinavian Cardiac Outcomes Trial-Lipid Lowering Ann ( ASCOT - LLA ) : a multicentre randomised controlled trial[J]. Lancet, 2003, 361:1 149-1 158.
  • 4FERON O, DESSY C, DESAGER J P, et al. Hydroxy - methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance[J]. Circulation, 2001, 103:113-118.
  • 5NISSEN S E, TUZCU E M, SCHOENHAGEN P, et al. Effect of intensive compared with moderate lipid - lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial [J]. JAMA, 2004,291:1 071-1 080.
  • 6CANNON C P, BRAUNWALD E, MCCABE C H, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004, 350:1 495 -1 504.
  • 7CORTI R, FUSTER V, FAYAD Z A, et al. Effects of aggressive versus conventional lipid - lowering therapy by simvastatin on hu- man atherosclerotic lesions: a prospective, randomized, double - blind trial with highresolution magnetic resonance imaging [ J ]. J Am Coll Cardiol, 2005, 46: 106- 112.
  • 8MARTIN VENTURA J L, BLANCO COLIO L M, GOMEZ HERNANDEZ A, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month[J]. Stroke, 2005, 36:1 796-1 800.
  • 9YU C M, ZHANG Q, LAM L, et al. Comparison of intensive and low - dose atorvastatin therapy in the reduction of carotid intimal - medial thickness in patients with coronary heart disease [ J ]. Heart, 2007, 93: 933- 939.
  • 10杨丽平,刘丽文,钱蕴秋,杨力军,李兰荪,何光彬,周晓东,沈敏.阿托伐他汀对冠心病患者颈动脉内-中膜厚度的影响[J].西北国防医学杂志,2007,28(2):104-106. 被引量：6

二级参考文献16

  • 1Alfon J, Guasch JF, Berrozpe M, et al. Nitric oxide synthase Ⅱ(NOS Ⅱ) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors[J].Atherosclerosis,1999,145(2):325-331.
  • 2Gotto FM. Lipid-lowering therapy for the primary prevention of coronary heart disease[J].J Am Coll Cardiol,1999,33:2078-2082.
  • 3Knapp AC, Huang J, Starling G, et al. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death[J].Atherosclerosis,2000,152:217-227.
  • 4Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor X Ⅲ and by enhancing factor Va inactivation[J].Circulation,2001,103:2248-2253.
  • 5Oukhadar C, Klein n, Prinz M, et al. Related articles. similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia[J].Thromb Haemost,2001,85:47-51.
  • 6Laufs U, Geryz K, Huang P, et al. Atorvastatin upregulates type Ⅲ nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31:2442-2449.
  • 7Brown BG, Zhao XQ. Importance of endothelial function in mediating the benefits of lipid-lowering therapy[J].Am J Cardiol,1998,82:49T-52T.
  • 8Brown Ms, Gold JL. A recepter-mediated pathway for cholesterol homeostasis[J].Science,1986,232:34-47.
  • 9Fukumoto Y, Libby P, et al.Statins alter smooth muscle ceel accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidmic rabbits[J].Circulation,2001,103:993-999.
  • 10O'Leary DH,Polak JF,Kponmal PA,et al.Carotid arteryintima and media thickness as a risk factor for myocardial infarction and stroke in older adults[ J ].N Engl J Med,1999,340(1):14 -22.

共引文献17

同被引文献256

引证文献15

二级引证文献51

广东医学
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部